Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashed A Ghandour

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Urology|December 23, 2014
Reply: To PMID 25440819Rashed A Ghandour, James M McKiernan
The Urologic Clinics of North America|July 7, 2019
Management of Stage II Germ Cell TumorsRashed A Ghandour, Nirmish Singla, Aditya Bagrodia
Current Opinion in Urology|July 16, 2019
Is cytoreductive nephrectomy relevant in the immunotherapy era?Nirmish Singla, Rashed A Ghandour, Vitaly Margulis
Expert Review of Anticancer Therapy|April 26, 2019
The use of cytoreductive nephrectomy in patients with renal cell carcinomaRashed A Ghandour, Nirmish Singla, Vitaly Margulis
Current Opinion in Urology|February 15, 2019
Sex differences in upper tract urothelial carcinomasNirmish Singla, Rashed A Ghandour, Vitaly Margulis
Translational Andrology and Urology|August 9, 2019
Biomarkers for platinum sensitivity in bladder cancer: are we there yet?Nirmish Singla, Rashed A Ghandour, Ganesh V Raj
Expert Opinion on Investigational Drugs|January 17, 2019
Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancerNirmish Singla, Rashed A Ghandour, Ganesh V Raj
Current Opinion in Urology|June 13, 2014
New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancerJennifer J Ahn, Rashed A Ghandour, James M McKiernan
Advances in Chronic Kidney Disease|June 20, 2015
Renal cell carcinoma: risks and benefits of nephron-sparing surgery for T1 tumorsRashed A Ghandour, Matthew R Danzig, James M McKiernan
European Urology Focus|November 24, 2019
Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell CarcinomaNirmish Singla, Yuval Freifeld, Rashed A Ghandour, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Urology|December 23, 2014
Reply: To PMID 25440819Rashed A Ghandour, James M McKiernan
The Urologic Clinics of North America|July 7, 2019
Management of Stage II Germ Cell TumorsRashed A Ghandour, Nirmish Singla, Aditya Bagrodia
Current Opinion in Urology|July 16, 2019
Is cytoreductive nephrectomy relevant in the immunotherapy era?Nirmish Singla, Rashed A Ghandour, Vitaly Margulis
Expert Review of Anticancer Therapy|April 26, 2019
The use of cytoreductive nephrectomy in patients with renal cell carcinomaRashed A Ghandour, Nirmish Singla, Vitaly Margulis
Current Opinion in Urology|February 15, 2019
Sex differences in upper tract urothelial carcinomasNirmish Singla, Rashed A Ghandour, Vitaly Margulis
Translational Andrology and Urology|August 9, 2019
Biomarkers for platinum sensitivity in bladder cancer: are we there yet?Nirmish Singla, Rashed A Ghandour, Ganesh V Raj
Expert Opinion on Investigational Drugs|January 17, 2019
Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancerNirmish Singla, Rashed A Ghandour, Ganesh V Raj
Current Opinion in Urology|June 13, 2014
New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancerJennifer J Ahn, Rashed A Ghandour, James M McKiernan
Advances in Chronic Kidney Disease|June 20, 2015
Renal cell carcinoma: risks and benefits of nephron-sparing surgery for T1 tumorsRashed A Ghandour, Matthew R Danzig, James M McKiernan
European Urology Focus|November 24, 2019
Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell CarcinomaNirmish Singla, Yuval Freifeld, Rashed A Ghandour, et al.
Pageof 3